Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
Public ClinicalTrials.gov record NCT00979251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
Study identification
- NCT ID
- NCT00979251
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Year to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2009 (Type not available)
- Primary completion
- May 2010 (Actual)
- Completion
- Aug 2011 (Actual)
- Last update posted
- Apr 14, 2014
2009 – 2011
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Adamas Investigational Site | San Francisco | California | 94114 | — |
| Adamas Investigational Site | San Francisco | California | 94115 | — |
| Adamas Investigational Site | San Francisco | California | — | — |
| Adamas Investigational Site | Hollywood | Florida | — | — |
| Adamas Investigational Site | Miramar | Florida | — | — |
| Adamas Investigational Site | Pinellas Park | Florida | — | — |
| Adamas Investigational Site | Honolulu | Hawaii | — | — |
| Adamas Investigational Site | Owensboro | Kentucky | — | — |
| Adamas Investigational Site | New Orleans | Louisiana | — | — |
| Adamas Investigational Site | Las Vegas | Nevada | — | — |
| Adamas Investigational Site | New York | New York | — | — |
| Adamas Investigational Site | Rapid City | South Dakota | 57702 | — |
| Adamas Investigational Site | Memphis | Tennessee | 38105 | — |
| Adamas Investigational Site | Amarillo | Texas | — | — |
| Adamas Investigational Site | Seattle | Washington | — | — |
| Adamas Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00979251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2014 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00979251 live on ClinicalTrials.gov.